ERCC2
ERCC2 (General transcription and DNA repair factor IIH helicase subunit XPD) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Skin cancer, Colorectal cancer and 5 more.
Overview
ATP-dependent 5'-3' DNA helicase. Component of the general transcription and DNA repair factor IIH (TFIIH) core complex, not absolutely essential for minimal transcription in vitro. Required for transcription-coupled nucleotide excision repair (NER) of damaged DNA; recognises damaged bases.
CIViC holds 23 clinical evidence items and 0 assertions across 15 variants, naming Chemotherapy, Immune Checkpoint Inhibitor, Paclitaxel and Carboplatin and others. Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes genetic literature 0.30, affected pathway 0.61, literature 0.99, genetic association 0.62, somatic mutation 0.95, animal model 0.60). IntOGen calls it a driver in 6 cohorts (6 activating, 0 loss-of-function), covering Bladder Urothelial Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ERCC2 (General transcription and DNA repair factor IIH helicase subunit XPD) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Skin cancer, Colorectal cancer and 5 more.
- 1 · What it is
ERCC2 (General transcription and DNA repair factor IIH helicase subunit XPD) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Skin cancer, Colorectal cancer and 5 more.
- 2 · What goes wrong in cancer
ATP-dependent 5'-3' DNA helicase. Component of the general transcription and DNA repair factor IIH (TFIIH) core complex, not absolutely essential for minimal transcription in vitro.
- 3 · How drugs use it
No product in this corpus aims at ERCC2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:3434 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P18074 (protein name, function text, keywords and locations (REST API)); CIViC gene ERCC2 (23 evidence items, 0 assertions, 15 variants; diseases: Bladder Carcinoma, Lung Non-small Cell Carcinoma, Bladder Urothelial Carcinoma, Melanoma, Osteosarcoma and 1 more (GraphQL API, CC0)); Open Targets ENSG00000104884 (association with cancer (MONDO_0004992) 0.83; per-cancer scores at or above 0.5: colorectal cancer 0.56, gastric cancer 0.50, urinary bladder cancer 0.73, ovarian cancer 0.51, melanoma 0.58, skin cancer 0.57 (GraphQL API, CC0)); IntOGen ERCC2 (driver in 6 cohorts (Act 6, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
ATP-dependent 5'-3' DNA helicase. Component of the general transcription and DNA repair factor IIH (TFIIH) core complex, not absolutely essential for minimal transcription in vitro. Required for transcription-coupled nucleotide excision repair (NER) of damaged DNA; recognises damaged bases. Sequestered in chromatin on UV-damaged DNA. When complexed to CDK-activating kinase (CAK), involved in transcription by RNA polymerase II. In NER, TFIIH acts by opening DNA around the lesion to allow the excision of the damaged oligonucleotide and its replacement by a new DNA fragment. Location: Nucleus; Cytoplasm, cytoskeleton, spindle (UniProt). Locus 19q13.32 (HGNC).
- Bladder & urothelial cancer: Open Targets association 0.73 with urinary bladder cancer (MONDO_0001187); CIViC evidence names this disease
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.56 with colorectal cancer (MONDO_0005575)
- Ovarian cancer: Open Targets association 0.51 with ovarian cancer (MONDO_0008170)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.50 with gastric cancer (MONDO_0001056)
- Melanoma: Open Targets association 0.58 with melanoma (MONDO_0005105); CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 5 therapies; IntOGen calls it an activating (Act) driver in 6 cohorts; CIViC holds 23 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ERCC2" OR ABSTRACT:"ERCC2" OR TITLE:"ERCC excision repair 2, TFIIH core complex helicase subunit" OR ABSTRACT:"ERCC excision repair 2, TFIIH core complex helicase subunit" OR TITLE:"General transcription and DNA repair factor IIH helicase subunit XPD" OR ABSTRACT:"General transcription and DNA repair factor IIH helicase subunit XPD" OR TITLE:"EM9" OR ABSTRACT:"EM9" OR TITLE:"MGC102762" OR ABSTRACT:"MGC102762" OR TITLE:"MGC126218" OR ABSTRACT:"MGC126218") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ERCC2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetRECQL4
Shares Osteosarcoma, Skin cancer (all types), IntOGen, Gastric & gastro-oesophageal junction cancer.
- TargetZNF217
Shares Osteosarcoma, CIViC, Ovarian cancer, Open Targets Platform.
- TargetALDH2
Shares Osteosarcoma, IntOGen, Open Targets Platform.
- TargetSQSTM1
Shares Osteosarcoma, Open Targets Platform.
- TargetCXCL10
Shares Osteosarcoma, CIViC.
- TreatmentCobolimab
Shares Osteosarcoma, Melanoma, Non-small-cell lung cancer.
- TrialA Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
Shares Osteosarcoma, Melanoma.
- InstitutionHôpital de la Timone, Assistance Publique-Hôpitaux de Marseille
Shares Osteosarcoma, Melanoma.